ArticleInvestigational new drugs2012

Phase I open-label study of cediranib, an oral inhibitor of VEGF signalling, in combination with the oral Src inhibitor saracatinib in patients with advanced solid tumours.

Tanja Trarbach et al.PubMed ↗Publisher ↗

No numbers read from the abstract.